Literature DB >> 7632937

Thrombocytopoietic properties of oncostatin M.

P M Wallace1, J F MacMaster, J R Rillema, J Peng, S A Burstein, M Shoyab.   

Abstract

Oncostatin M (OM) is a 28-kD glycoprotein that exhibits a panoply of biologic effects. Based on histologic observations of increased splenic megakaryocytes in nude mice implanted with an OM-secreting cell line, the thrombocytopoietic properties of OM in mice were investigated in culture and in vivo. Alone, OM did not induce megakaryocytic colony formation, but in combination with murine interleukin-3 (IL-3), OM markedly enhanced colony formation. The effects of OM on colony formation were similar to those of IL-6. OM alone augmented acetylcholinesterase in short-term marrow cultures. In normal mice, the administration of OM augmented platelet counts without increasing other circulating blood cell counts. The increment in counts exceeded that observed with IL-6. The kinetics of the OM response suggested that maximal increases in platelets occurred 3 days after the cessation of OM administration, irrespective of the duration of administration. In irradiated mice, OM administration accelerated platelet recovery and prevented the decrease in red blood cells observed in irradiated control animals. The data show that OM behaves as a megakaryocytic maturation factor in vitro and augments platelet production in vivo. Based on these animal data, OM may have potential clinical utility as a thrombocytopoietic agent.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7632937

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Oncostatin m maintains the hematopoietic microenvironment and retains hematopoietic progenitors in the bone marrow.

Authors:  Ken-ichi Minehata; Masaki Takeuchi; Yoko Hirabayashi; Tohru Inoue; Peter J Donovan; Minoru Tanaka; Atsushi Miyajima
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

2.  Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis.

Authors:  Gregor Hoermann; Sabine Cerny-Reiterer; Andrea Perné; Miriam Klauser; Konrad Hoetzenecker; Katharina Klein; Leonhard Müllauer; Marion Gröger; Sebastian M B Nijman; Walter Klepetko; Peter Valent; Matthias Mayerhofer
Journal:  Am J Pathol       Date:  2011-03-31       Impact factor: 4.307

3.  Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family.

Authors:  G Senaldi; B C Varnum; U Sarmiento; C Starnes; J Lile; S Scully; J Guo; G Elliott; J McNinch; C L Shaklee; D Freeman; F Manu; W S Simonet; T Boone; M S Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

4.  Functional regions of the mouse thrombopoietin receptor cytoplasmic domain: evidence for a critical region which is involved in differentiation and can be complemented by erythropoietin.

Authors:  F Porteu; M C Rouyez; L Cocault; L Bénit; M Charon; F Picard; S Gisselbrecht; M Souyri; I Dusanter-Fourt
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

Review 5.  Megakaryocyte Contribution to Bone Marrow Fibrosis: many Arrows in the Quiver.

Authors:  Alessandro Malara; Vittorio Abbonante; Maria Zingariello; Annarita Migliaccio; Alessandra Balduini
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-11-01       Impact factor: 2.576

6.  Roles of IL-6-gp130 Signaling in Vascular Inflammation.

Authors:  Tieying Hou; Brian C Tieu; Sutapa Ray; Adrian Recinos Iii; Ruwen Cui; Ronald G Tilton; Allan R Brasier
Journal:  Curr Cardiol Rev       Date:  2008-08

7.  Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects.

Authors:  U A Betz; W Bloch; M van den Broek; K Yoshida; T Taga; T Kishimoto; K Addicks; K Rajewsky; W Müller
Journal:  J Exp Med       Date:  1998-11-16       Impact factor: 14.307

8.  In vivo affinity and target engagement in skin and blood in a first-time-in-human study of an anti-oncostatin M monoclonal antibody.

Authors:  Juliet Reid; Stefano Zamuner; Ken Edwards; Sally-Anne Rumley; Katherine Nevin; Maria Feeney; Chiara Zecchin; Disala Fernando; Nicolas Wisniacki
Journal:  Br J Clin Pharmacol       Date:  2018-07-12       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.